O-RAN-ALLIANCE
22.10.2021 09:38:11 CEST | Business Wire | Press release
O-RAN ALLIANCE has released another set of technical specifications for open RAN published since July 2021. Initial versions of nine technical specifications comprise:
- O-RAN Non-Real-Time RAN Intelligent Controller (RIC) Architecture
- Near-Real-Time RIC and E2 Interface: Use Cases and Requirements v1.0
- O-RAN E2 Service Model: RAN Control (E2SM-RC) v1.0
- O-RAN O1 Interface specification for O-CU-UP and O-CU-CP towards the Service Management and Orchestration (SMO) framework
- O-RAN Acceleration Abstraction Layer FEC Profiles
- Infrastructure management services of the O2 interface
- O-Cloud Notification API Specification for Event Consumers
- O-RAN Xhaul Transport Testing Specification
- O-RAN Security Requirements Specifications
Another 39 technical documents bring extensions and new features to the existing specifications. All new specifications will soon be available on our website . To learn more, please read our blog post .
3rd O-RAN ALLIANCE Global Plugfest Underway with 77 companies at 7 venues
O-RAN ALLIANCE’s 3rd Global Plugfest has been in progress since summer 2021. 77 companies perform testing, integration or proofs of concept in 7 venues around the world. Technical work is planned to continue till the end of November 2021, with subsequent presentations of the results in our Plugfest Virtual Showcase .
18 demos of O-RAN technology prepared for MWC Los Angeles 2021 or the O-RAN Virtual Exhibition
Five O-RAN demonstrations are planned to be presented at the MWC Los Angeles 2021.
Parallel Wireless demonstrates its Open RAN, ALL G - 2G, 3G, 4G, and 5G, O-RAN compliant software platform showcasing an open, secure, and intelligent RAN architecture to deliver wireless connectivity, enabling people to be connected whenever, wherever, and however they choose. Visit the demo at South 2505Ex.
VMware Telco Cloud Platform RAN, powered by Dell EMC PowerEdge server and Intel FlexRAN, delivers flexibility to open RAN. The demo showcases the platform’s horizontal design and automation capabilities with 3 simple steps to deploy and programmatically provision the platform with Kubernetes to run Altiostar ’s vRAN functions. Visit the demo at Booth 1210.
VMware demonstrates the power of VMware RIC SDKs, enabling its partners to accelerate the development of their xApp/rApp; creating a vibrant application ecosystem. We bring the intelligence and innovation to the RAN faster. Visit the demo at Booth 1210.
Northeastern University showcases how Colosseum can be used to (i) instantiate a fully programmable end-to-end network controlled by O-RAN-compliant near-real-time RIC; (ii) collect performance datasets from the RAN, and (iii) implement AI-based control of the RAN through xApps and programmable software stacks. Visit the demo at Booth 1444.
Cohere Technologies and VMware demonstrate how Cohere’s 5G MU-MIMO Spectrum Multiplier xApp running on VMware RIC controls multiple UEs simultaneously in the same time and frequency slots to drastically boost capacity. Visit us to learn how we successfully demonstrated these technologies to a major European operator. Visit the demo at Booth 1210.
13 more virtual demos for MWC Los Angeles 2021 have enriched the O-RAN Virtual Exhibition :
MiTAC demonstrates a private 5G E2E O-RAN solution with O1 Interface based on 3rd Generation Intel® Xeon® Scalable Processors and integrated with an indoor O-RU which supports MIMO and 4T4R via Open Front Haul Interface.
CIG and partners demonstrate an open 5G small cell solution. The E2E solution comprises O-CU and O-DU in one O-DU box, with L2/L3 SW, L1 SW and HW from different vendors. Both O-DU and O-RU are designed with COTS components and open interfaces. A fronthaul gateway is also available as part of the open solution.
IPLOOK demonstrates a full stack cloud-native and container-based system of end-to-end 4G/5G converged mobile core solution for operators and enterprises.
STL demonstrated 5G Small Cell Split 7.2 O-RU (GARUDA) Interworking with ASOCS 5G NR SA Evaluation Kit (Cyrus 2.0), based on O-RAN IoT profiles. The setup included STL O-RU and ASOCS EVK (DU, CU, Core VM and CPE). The scenarios demonstrated PDU session establishment (registration procedure), followed by CUS-plane and M-plane connectivity.
University of Utah showcases O-RAN-based, xApp-controlled RAN slicing using the experiment workflows in the POWDER platform. We combine O-RAN with an open-source mobility stack, provide a top-to-bottom RAN application via the RIC, and deploy in a realistic wireless environment. This software is open-source and packaged in POWDER to enable further experimentation.
IS-Wireless showcases the next level of software disaggregation in 5G OpenRAN with protocol layers working as independent VNFs on various computing platforms: O-DU VNF/CNF on Edge Cloud (COTS HW), O-CU VNF on Core/Regional Cloud. The company achieved E2E connectivity on 5G with split option 7.2 and option 2.
Dell Technologies is working with an open ecosystem of partners to develop validated solutions. Together with Intel, VMware, Mavenir, Dell has developed a cloud-native Open RAN reference architecture available as a technology preview. The reference architecture offers a complete solution deployed on Dell EMC PowerEdge XR11, XR12 and R750 servers.
Rohde & Schwarz provides an explanation and demo about the measurement of roundtrip latency on IP layer in O-RAN and legacy networks. The IP layer is the basis for the application layer latency. Real-time and interactive applications are rapidly increasing. These applications need to be supported by 5G and other technologies. A latency comparison over different network types can be achieved.
VIAVI demonstrates the power of test case libraries to accelerate validation of disaggregated network performance, interoperability and security according to O-RAN defined test specifications. The TM500 UE Emulator Test Case Libraries leverage unmatched TM500 functional coverage and VIAVI expertise. Network performance is validated using extensive KPI monitoring and automated log analysis to quickly indicate compliance with the O-RAN test specifications.
Keysight and Auray partner in Auray OTIC and Security Lab for Certification and Badging of O-RAN solutions by performing Conformance Test, IOT Test and E2E Test services based on corresponding test solutions with a comprehensive mechanism ensuring openness, interoperability and conformity of O-RAN solutions from ecosystem players for both operators and vendor community.
Keysight Technologies showcases the Performance Benchmarking Solution (PBM) that directly controls Real UEs across device models and chipsets to automatically conduct tests as defined in TIFG E2E test specifications in both lab and field in a multi-vendor O-RAN environment.
CMCC and Inspur demonstrate a QoE assurance application deployed on the Near-RT RIC, providing the capabilities of QoE aware and intelligent RAN Control by collecting RAN measurements as well as sending control command (e.g., maximum MCS configuration) through E2 interface. This demo is validated in some industry scenarios.
Juniper Networks and VIAVI Solutions demonstrate successful transport of Open Fronthaul over a packet-switched network. Juniper's ACX Series routers, used as CSR/HSR, provide fronthaul transport connectivity. VIAVI's O-RU and O-DU emulators generate O-RAN compliant Open Fronthaul traffic (CU and M-plane), while VIAVI’s MTS-5800 fronthaul tester verifies the fronthaul transport/sync network.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211022005120/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom